NCT04538664 2026-04-13PAPILLONJanssen Research & Development, LLCPhase 3 Active not recruiting308 enrolled 12 charts 2 FDA
NCT05388669 2026-04-13PALOMA-3Janssen Research & Development, LLCPhase 3 Active not recruiting418 enrolled 16 charts 1 FDA
NCT05663866 2026-04-13Premedication to Reduce Amivantamab Associated Infusion Related ReactionsJanssen Research & Development, LLCPhase 2 Active not recruiting68 enrolled 12 charts